Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof

Abstract

Genetically engineered hematopoietic cells, which express one or more factors that redirect glucose metabolites, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide, a chimeric antigen receptor (CAR) polypeptide, or a TCR polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Dependencies are inferred from the claim text.